NCT00452374 - Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Leukemia

Interventions

DRUG

Cytarabine

1 g/m\^2 given IV for two days (Days 2 and 3).

DRUG

Fludarabine

30 mg/m\^2 given IV for two days (Days 2 and 3).

DRUG

Oxaliplatin

Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).

DRUG

Rituximab

375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.

Trial Locations (2)

University of California-San Diego, La Jolla

Dana-Farber Cancer Institute, Boston